



Hostile femoral access in patients undergoing TAVR



What's the best choice?

Kentaro Hayashida MD, PhD, FESC, FACC, FJCS

Disclosure


A clinical proctor for Edwards Lifesciences, Medtronic, and Abbott

Hostile femoral access and major vascular complication



TF approach in most cases

Sapien 3
Ultra RESILIA



14-16 Fr
E sheath+

Navitor




14-15 Fr
Integrated sheath

Evolut FX




14 Fr
In-line sheath

How far can we negotiate?




Impossible




Challenging, but doable

TF-TAVI




Started from the left side
but we could not advance the sheath




Successfully advanced the sheath to
the terminal aorta

Need some negotiation even in the abdominal aorta



Alternative access trend




Alternative accesses


- **Transapical**
- **Transaortic**
- **Transabdominal**
- **Transiliac**
- **Transaxillary**
- **Transcarotid**
- **Transcaval**



Decision flowchart choosing TAVR access



TAVR in patients with PAD: The Hostile registry




1707 patients

TF+percutaneous 518 (30.3%), Transthoracic 642 (37.6%), Non-Transthoracic 547 (32.0%)

- Both TFA and TAA: lower 30-day rates of MAE, driven by fewer access complications
- TF compared with non-transthoracic was associated with lower 1-year risk of stroke

Transaxillary access, TAXI registry

SE: lower vascular complications



Transcarotid vs. transaxillary

Cardiovascular Revascularization Medicine 33 (2021) 20–25



Contents lists available at ScienceDirect
Cardiovascular Revascularization Medicine



Transaxillary compared with transcarotid access for TAVR: a propensity-matched comparison from a French multicentre registry

Outcomes of Transcarotid Versus Trans-Subclavian Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis



Mostafa R. Amer^a, Wassim Mosleh^b, Michael Megaly^c, Tanvi Shah^d, Yinn Shaung Ooi^e, Raymond G. McKay^{e,*}



Nicolas Debry^{1,2,*}, MD; Talel Raouf Trimech^a, MD; Thomas Gandet¹, MD; Flavien Vincent^{1,2}, MD, PhD; Ilir Hysi^a, MD; Cédric Delhayé¹, MD; Guillaume Cayla¹, MD, PhD; Mohamad Koussa¹, MD; Francis Juthier^{2,3}, MD, PhD; Florence Leclercq¹, MD; Max Pécheux³, MD; Saïd Ghostine^a, MD; Julien Labreuche^a; Thomas Modine¹, MD, PhD; Eric Van Belle^{1,2}, MD, PhD



Meta-analysis
Similar 30-day outcomes
A trend towards higher rates of major vascular complications and pacemaker with the TAX

Propensity-match comparison
1M mortality, stroke/TIA and 1-year mortality were similar
Transcarotid access was accompanied by more minor bleeding and main access hematoma

CRM 2021

EuroIntervention 2020


Transcaval TAVR



19 cases, successful in 17 cases
6 major vascular complication

Greenbaum et al. JACC 2014

Transcaval access is reaching maturity



JACC: CARDIOVASCULAR INTERVENTIONS
 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF
 CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE
 CC BY LICENSE (<http://creativecommons.org/licenses/by/4.0/>).

VOL. 16, NO. 4, 2023

STATE-OF-THE-ART REVIEW


Transcaval Access and Closure Best Practices

Robert J. Lederman, MD,^a Adam B. Greenbaum, MD,^b Jaffar M. Khan, PhD, BMBCr,^{a,c} Christopher G. Bruce, MBCrB,^a
 Vasilis C. Babaliaros, MD,^b Toby Rogers, PhD, BMBCr^{a,d}

Lederman RJ, et al. J Am Coll Cardiol Intv. 2023;16(4):371-395.

Transcaval versus transaxillary TAVR

Transcaval vs Transaxillary Access for TAVR, N = 344



- 8 US centers
- Transcaval TAVR had lower rates of stroke and similar bleeding compared with transaxillary access
- Both approaches had more complications than transfemoral access

In-Hospital Events	Transcaval (n = 238)	Transaxillary (n = 106)	Transfemoral (n = 7,132)
Stroke or TIA	3% *	13%	2%
Bleeding †	10%	13%	4%
Death	4%	4%	1%
Discharge home without stroke/TIA	88% *	62%	90%

* $P < 0.001$ Transcaval vs Transaxillary

† Major or life-threatening bleeding (VARC-3 \geq Type 2)

Internal Endoconduit for Unfavorable Iliac Artery for TAVR



Conclusion

- Hostile femoral access is sometimes challenging
- Transaxillary access is less invasive, but may be associated with higher risk of stroke
- Transcarotid approach demonstrates similar results with less stroke compared to transaxillary access
- Transcaval approach is reaching its maturity
- Avoiding complication by meticulous screening and patient selection are important
- Don't forget SAVR!